Research graph
References from Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration. Local targets link to admitted publications; unresolved targets remain external evidence.
Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study
10.3324/haematol.2024.286886 · 2025 · External reference
Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders
10.1182/blood.2023022193 · 2024 · External reference
10.1016/s2352-3026(26)00173-0 · 2026 · Admitted local publication
Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
10.1016/s2352-3026(25)00320-5 · 2026 · External reference
The epidemiology of thalassaemia syndromes in southeast Asia
2026 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2025 · External reference
Haemoglobinopathies in Europe: health & migration policy perspectives
10.1186/1750-1172-9-97 · 2014 · External reference
An assessment of the continuing medical education needs of US physicians in the management of patients with beta thalassemia
10.1007/s00277-020-04246-5 · 2021 · External reference
Syrian refugees and their impact on health service delivery in the pediatric hematology/oncology clinics across Canada
10.1097/mph.0000000000001524 · 2020 · External reference
The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders
10.1155/2013/727905 · 2013 · External reference
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia
10.1182/blood-2012-10-408021 · 2013 · External reference
Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea
10.1056/nejm198404053101401 · 1984 · External reference
Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia
10.3109/03630269708997382 · 1997 · External reference
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
10.1056/nejm199505183322001 · 1995 · External reference
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
10.1016/s0140-6736(11)60355-3 · 2011 · External reference
Real-life experience with hydroxyurea in patients with sickle cell disease: results from the prospective ESCORT-HU cohort study
10.1002/ajh.26286 · 2021 · External reference
Hydroxyurea-inducible SAR1 gene acts through the Giα/JNK/Jun pathway to regulate γ-globin expression
10.1182/blood-2013-10-534842 · 2014 · External reference
Efficacy and safety of hydroxyurea therapy on patients with β-thalassemia: a systematic review and meta-analysis
10.3389/fmed.2024.1480831 · 2025 · External reference
Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebocontrolled, phase 3 trial
10.1016/s0140-6736(26)00874-3 · 2026 · External reference
A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia
10.1056/nejmoa1910182 · 2020 · External reference
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(25)00635-x · 2025 · External reference
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
10.1016/s2352-3026(22)00208-3 · 2022 · External reference
The use of hydroxyurea in the real life of MIOT network: an observational study
10.1080/14740338.2022.2064980 · 2022 · External reference
Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications
2004 · External reference
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study
10.1182/blood-2009-09-243154 · 2010 · External reference
A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia
10.1038/s41598-022-06774-8 · 2022 · External reference
Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias
2016 · External reference
Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India
10.1016/j.cca.2009.06.019 · 2009 · External reference
Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients
10.1111/j.1365-2141.2010.08397.x · 2010 · External reference
Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up
10.1111/j.1365-2141.2006.06002.x · 2006 · External reference
Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis
10.1007/s12185-017-2307-0 · 2017 · External reference
Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia
10.1111/ejh.12204 · 2014 · External reference
Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients
10.1111/ejh.12182 · 2013 · External reference
Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience
10.1007/s00277-021-04627-4 · 2021 · External reference
Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia
10.1111/j.1537-2995.2007.01399.x · 2007 · External reference
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
10.1002/ajh.21699 · 2010 · External reference
Safety of hydroxyurea in pregnancy: a systematic review of the literature
10.1016/j.jogc.2025.102924 · 2025 · External reference
Protein degraders—from thalidomide to new PROTACs
10.1093/jb/mvad113 · 2024 · External reference
Effects of thalidomide on metabolism and lifespan of red blood cell in patients with β-thalassemia major: a post hoc analysis of a randomized controlled trial
10.1016/j.clinthera.2025.01.008 · 2025 · External reference
Thalidomide confers therapeutic benefit in beta thalassemia patients by enhancing hemoglobin and hematopoietic gene expression: a non-randomized clinical trial
2025 · External reference
Efficacy and safety of thalidomide in β-thalassaemia: a systematic review and meta-analysis
10.1038/s41598-026-46504-y · 2026 · External reference
Association of CYP2C19 gene single nucleotide polymorphisms (rs12248560 and rs4244285) with response to thalidomide in transfusion dependent β-thalassemia patients—a 12-months follow-up study
10.1080/14622416.2026.2622318 · 2025 · External reference
Genetic modifiers of response to thalidomide in transfusion-dependent beta-thalassemia patients: a whole-exome sequence analysis
10.7717/peerj.20038 · 2025 · External reference
Clinical efficacy of thalidomide for various genotypes of beta thalassemia
10.1186/s12920-024-01963-y · 2024 · External reference
Predictors of hematologic responses in patients with non-transfusion-dependent β-thalassemia receiving thalidomide therapy
2022 · External reference
Efficacy of thalidomide treatment in children with transfusion dependent β-thalassemia: a retrospective clinical study
2021 · External reference
Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial
10.1038/s41392-021-00811-0 · 2021 · External reference
The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients
10.1016/j.bcmd.2020.102442 · 2020 · External reference
Thalidomide in patients with transfusion-dependent e-beta thalassemia refractory to hydroxyurea: a single-center experience
10.1007/s12288-020-01263-2 · 2020 · External reference
Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia—a pilot study from a tertiary care centre of India
10.1016/j.bcmd.2021.102544 · 2021 · External reference
Evaluating health-related quality of life in thalassemia: low-dose thalidomide vs. standard care-insights from a comparative study
10.1080/03630269.2025.2473526 · 2025 · External reference
Effects of thalidomide on endothelial activation and stress index in children with β-thalassemia major
2024 · External reference
Efficacy and safety of thalidomide (1 vs 2 mg/kg/d) in transfusion-dependent thalassemia: a non-inferiority trial
10.1182/bloodadvances.2025019459 · 2026 · External reference
Comparison of efficacy and safety outcomes of different doses schedules of thalidomide for treating moderate-to-severe β-thalassemia patients
10.2147/tcrm.s481128 · 2024 · External reference
Long-term follow-up of patients undergoing thalidomide therapy for transfusion-dependent β-thalassaemia: a single-center experience
10.2147/ijgm.s462991 · 2024 · External reference
Acute lymphoblastic leukemia developing in children with thalassemia exposed to thalidomide: a case series
10.1007/s13312-025-3363-9 · 2025 · External reference
Thalidomide-induced primary amenorrhea in a patient with HbE/beta-thalassemia
2023 · External reference
Secondary amenorrhea in a β-thalassemia major patient treated with thalidomide
10.1002/pbc.30982 · 2024 · External reference
Thalidomide and hydroxyurea in transfusion-dependent thalassemia: efficacy, safety profile and impact on quality of life
10.1080/03630269.2024.2386076 · 2024 · External reference
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients
10.1007/s00277-021-04501-3 · 2021 · External reference
Safety and efficacy of thalidomide and hydroxyurea combination in beta thalassemia patients
10.1007/s12288-022-01536-y · 2023 · External reference
Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia
10.1182/bloodadvances.2022007031 · 2022 · External reference
Safety and effectiveness of thalidomide and hydroxyurea combination in β-thalassaemia intermedia and major: a retrospective pilot study
10.1111/bjh.16272 · 2020 · External reference
A phase 2 randomized controlled trial of single-agent hydroxyurea versus thalidomide among adult transfusion dependent β thalassemia patients
10.1007/s12288-022-01620-3 · 2023 · External reference
High-level induction of fetal haemoglobin by pomalidomide in β-thalassaemia/HbE erythroid progenitor cells
10.1111/bjh.16670 · 2020 · External reference
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
10.1172/jci32322 · 2008 · External reference
Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy
10.1111/jth.15354 · 2021 · External reference
ThalPred: a web-based prediction tool for discriminating thalassemia trait and iron deficiency anemia
10.1186/s12911-019-0929-2 · 2019 · External reference
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent β-thalassemia in the United States
10.1080/13696998.2026.2649528 · 2026 · External reference
Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia
10.1080/20016689.2021.1922028 · 2021 · External reference
A communitarian approach to cell therapy and gene therapy access in low-income and middle-income countries
10.1016/s2352-3026(25)00282-0 · 2025 · External reference
Thailand's emerging role in the cell and gene therapy revolution: a review of progress and potential
10.1111/cts.70561 · 2026 · External reference
Gene therapy in China: past, present, and future
10.1016/s2352-3026(22)00356-8 · 2022 · External reference
New rules spur cell and gene therapy trials in China
10.1038/s41587-026-03065-9 · 2026 · External reference
Futuristic global cell and gene therapy regulations based on a review of today's leading frameworks
10.1016/j.jcyt.2026.102064 · 2026 · External reference
CRISPR-based therapeutic genome editing for inherited blood disorders
10.1038/s41573-025-01236-y · 2025 · External reference
Pathing the way from regulatory approval to market access for gene therapy products (GTPs): an integrative review in the US, EU5, Japan and China
2026 · External reference
A dual-modal machine learning framework integrating red blood indices and smartphone-captured microscopic images for β-thalassemia screening
10.1186/s12911-026-03451-y · 2026 · External reference
Applications of artificial intelligence in thalassemia: a comprehensive review
10.3390/diagnostics13091551 · 2023 · External reference
Comparison of the diagnostic performance of machine learning algorithms for differentiating iron deficiency anemia and thalassemia
10.1007/s00277-026-06894-5 · 2026 · External reference
Basrah score: a novel machine learning-based score for differentiating iron deficiency anemia and beta thalassemia trait using RBC indices
10.3389/fdata.2025.1634133 · 2025 · External reference
Predicting thalassemia using deep neural network based on red blood cell indices
10.1016/j.cca.2023.117329 · 2023 · External reference
Prediction of β-thalassemia carriers using complete blood count features
10.1038/s41598-022-22011-8 · 2022 · External reference
Machine learning-based prediction of β-thalassemia trait using red blood cell indices
10.1111/ijlh.70017 · 2026 · External reference
An online alpha-thalassemia carrier discrimination model based on random forest and red blood cell parameters for low HbA2 cases
10.1016/j.cca.2021.12.003 · 2022 · External reference
From CBC to clarity: interpretable detection of beta-thalassemia carriers in imbalanced datasets
10.1371/journal.pone.0331985 · 2025 · External reference
Machine learning for discriminating microcytic hypochromic anemia based on erythrocyte parameters
10.1111/ijlh.14524 · 2025 · External reference
Machine learning approach for differentiating iron deficiency anemia and thalassemia using random forest and gradient boosting algorithms
10.1038/s41598-025-01458-5 · 2025 · External reference
Detection of β-thalassemia trait from a heterogeneous population with red cell indices and parameters
10.1016/j.compbiomed.2025.110151 · 2025 · External reference
MultiThal-classifier, a machine learning-based multi-class model for thalassemia diagnosis and classification
10.1016/j.cca.2024.120025 · 2025 · External reference
Machine learning-based prediction of hemoglobinopathies using complete blood count data
10.1093/clinchem/hvae081 · 2024 · External reference
Discrimination of β-thalassemia and iron deficiency anemia through extreme learning machine and regularized extreme learning machine based decision support system
10.1016/j.mehy.2020.109611 · 2020 · External reference
Prediction of β-thalassemia carrier using federated learning and explainable AI
2026 · External reference
A comprehensive case study of deep learning on the detection of alpha thalassemia and beta thalassemia using public and private datasets
10.1038/s41598-025-97353-0 · 2025 · External reference
Establishment and verification of the model in diagnosis of thalassemia trait based on red blood cell parameters: a two-center retrospective study
2025 · External reference
The TVGH-NYCU Thal-Classifier: development of a machine-learning classifier for differentiating thalassemia and non-thalassemia patients
10.3390/diagnostics11091725 · 2021 · External reference
Role of red cell indices in screening for beta thalassemia trait: an assessment of the individual indices and application of machine learning algorithm
10.1007/s12288-020-01373-x · 2021 · External reference
The application of machine-learning algorithms for multiclass classification of microcytic anemia revealed that a minimum required number of hematological parameters is enough to achieve high diagnostic accuracy
10.1111/ijlh.70033 · 2026 · External reference
Classification of α-thalassemia data using machine learning models
10.1016/j.cmpb.2024.108581 · 2025 · External reference
Machine learning and AI-assisted red blood cell morphology analysis for effective thalassemia screening
10.1007/s00277-026-06860-1 · 2026 · External reference
Enhancing thalassemia gene carrier identification in non-anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning
10.1111/ejh.14160 · 2024 · External reference
Image analysis using machine learning for automated detection of hemoglobin H inclusions in blood smears—a method for morphologic detection of rare cells
10.4103/jpi.jpi_110_20 · 2021 · External reference
Deep learning assisted automated assessment of thalassaemia from haemoglobin electrophoresis images
10.3390/diagnostics12102405 · 2022 · External reference
Development and validation of an interpretable risk prediction model for the early classification of thalassemia
10.1038/s41746-025-01766-0 · 2025 · External reference
Multiclass classification of thalassemia types using complete blood count and HPLC data with machine learning
10.1038/s41598-025-06594-6 · 2025 · External reference
Accurate diagnosis of hemoglobinopathies with machine learning based on high-throughput proteomics
10.1002/hem3.70227 · 2025 · External reference
Machine learning improves detection of alpha thalassemia carriers compared to clinical features
10.1038/s41598-025-20605-6 · 2025 · External reference
DeepThal: a deep learning-based framework for the large-scale prediction of the α+-thalassemia trait using red blood cell parameters
10.3390/jcm11216305 · 2022 · External reference
Evaluation of low-cost techniques to detect sickle cell disease and β-thalassemia: an open-label, international, multicentre study
2025 · External reference
Prevalence of thalassemia in the Vietnamese population and building a clinical decision support system for prenatal screening for thalassemia
10.4084/mjhid.2023.026 · 2023 · External reference
A hybrid MCDM and machine learning framework for thalassemia risk assessment in pregnant women
10.3390/diagnostics15222833 · 2025 · External reference
Development of an interpretable ensemble learning model for thalassemia detection in pregnant women using routine hematological parameters
2025 · External reference
Performance analysis of machine learning algorithms and screening formulae for β-thalassemia trait screening of Indian antenatal women
10.1016/j.ijmedinf.2022.104866 · 2022 · External reference
Interpretable machine learning models for beta thalassemia prediction: an explainable AI approach for smart healthcare 5.0
10.3389/fmed.2025.1688645 · 2026 · External reference
TT@MHA: a machine learning-based webpage tool for discriminating thalassemia trait from microcytic hypochromic anemia patients
10.1016/j.cca.2023.117368 · 2023 · External reference
Support vector machine-based formula for detecting suspected α thalassemia carriers: a path toward universal screening
10.3390/ijms25126446 · 2024 · External reference
Thalassaemia prevention in Asia: progress, challenges, and future directions
2026 · External reference
Convolutional neural networks for automatic MR classification of myocardial iron overload in thalassemia major patients
10.1007/s00330-024-11245-x · 2025 · External reference
MRI deep learning-based automatic segmentation of interventricular septum for black-blood myocardial T2* measurement in thalassemia
10.1002/jmri.29113 · 2024 · External reference
Deep learning staging of liver iron content from multiecho MR Images
10.1002/jmri.28300 · 2023 · External reference
A mixed-attention network for automated interventricular septum segmentation in bright-blood myocardial T2* MRI relaxometry in thalassemia
10.1016/j.acra.2025.04.075 · 2025 · External reference
Beyond diagnosis: a systematic review of artificial intelligence and deep learning in monitoring iron overload and organ toxicity in beta-thalassemia
10.1080/03630269.2026.2653733 · 2026 · External reference
Prediction of heart and liver iron overload in β-thalassemia major patients using machine learning methods
10.1080/03630269.2022.2158100 · 2022 · External reference
Machine learning in the prediction of liver iron concentration and iron chelation therapy adjustment
10.1080/16078454.2026.2647314 · 2026 · External reference
Effect of genetic polymorphisms on the pharmacokinetics of deferasirox in healthy Chinese subjects and an artificial neural networks model for pharmacokinetic prediction
10.1007/s13318-020-00647-z · 2020 · External reference
A predictive model for low bone mass in pediatric and adolescent patients with transfusion-dependent beta-thalassemia
10.21037/tp-2025-385 · 2025 · External reference
Explainable AI framework for improved thalassemia mental health classification and feature selection
10.1371/journal.pone.0341168 · 2026 · External reference
Construction of an exposure-pathway-phenotype in children with depression due to transfusion-dependent thalassemia: results of (un)supervised machine learning
10.1016/j.jad.2020.12.089 · 2021 · External reference
Comparison between an artificial neural network and logistic regression in predicting acute graft-vs-host disease after unrelated donor hematopoietic stem cell transplantation in thalassemia patients
10.1016/j.exphem.2010.02.012 · 2010 · External reference
Enhancing survival analysis through federated learning in non-IID and scarce data scenarios
10.1016/j.compbiomed.2026.111558 · 2026 · External reference
Web-based expert system with quick response code for beta-thalassemia management
10.1177/1460458221989397 · 2021 · External reference
A smart chatbot for interactive management in beta thalassemia patients
2022 · External reference
The influence of treatment in specialized centers on survival of patients with thalassemia major
10.1002/ajh.21398 · 2009 · External reference
TIF standards for haemoglobinopathy reference centres
10.3390/thalassrep13010002 · 2023 · External reference
Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective
10.1016/s2352-3026(23)00182-5 · 2023 · External reference
Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration
10.1002/mrm.24854 · 2014 · External reference
Intersite validations of the pixel-wise method for liver R2* analysis in transfusion-dependent thalassemia patients: a more accessible and affordable diagnostic technology
10.5144/1658-3876.2012.91 · 2012 · External reference
Inter-site validations of the Pixel-Wise method for cardiac T2* analysis in transfusion-dependent Thai thalassemia patients
2012 · External reference
Ultrafast magnetic resonance imaging for iron quantification in thalassemia participants in the developing world: the TIC-TOC study (Thailand and UK International Collaboration in Thalassaemia Optimising Ultrafast CMR)
10.1161/circulationaha.116.022803 · 2016 · External reference
Heart and liver T2 assessment for iron overload using different software programs
10.1007/s00330-011-2208-1 · 2011 · External reference
Primary HBB gene mutation severity and long-term outcomes in a global cohort of β-thalassaemia
10.1111/bjh.17897 · 2022 · External reference
The International Hemoglobinopathy Research Network (INHERENT): an international initiative to study the role of genetic modifiers in hemoglobinopathies
10.1002/ajh.26323 · 2021 · External reference
The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry
10.1182/bloodadvances.2022007823 · 2023 · External reference
An ICET-A survey on occult and emerging endocrine complications in patients with β-thalassemia major: conclusions and recommendations
2019 · External reference
Global Globin Network consensus paper: classification and stratified roadmaps for improved thalassaemia care and prevention in 32 countries
10.3390/jpm12040552 · 2022 · External reference
